Publications des scientifiques de l'IRD

Engone-Ondo J. D., Mouinga-Ondeme A., Lekana-Douki S. E., Diane A., Mamimandjiami A. I., Banga O., Ndong-Atome G. R., Aghokeng Fobang Avelin. (2021). High rate of virological failure and HIV drug resistance in semi-rural Gabon and implications for dolutegravir-based regimen efficacy. Journal of Antimicrobial Chemotherapy, 76 (4), p. 1051-1056. ISSN 0305-7453.

Titre du document
High rate of virological failure and HIV drug resistance in semi-rural Gabon and implications for dolutegravir-based regimen efficacy
Année de publication
2021
Type de document
Article référencé dans le Web of Science WOS:000648949200030
Auteurs
Engone-Ondo J. D., Mouinga-Ondeme A., Lekana-Douki S. E., Diane A., Mamimandjiami A. I., Banga O., Ndong-Atome G. R., Aghokeng Fobang Avelin
Source
Journal of Antimicrobial Chemotherapy, 2021, 76 (4), p. 1051-1056 ISSN 0305-7453
Background: The projected UNAIDS goal of ending AIDS by 2030 requires significant global efforts to improve current and future ART strategies. In this study, we assessed viral load (VL) suppression and acquired drug resistance, as well as future efficacy of dolutegravir-based combinations for patients Living in semi-rural regions of Gabon. Methods: Eligible study participants were adults receiving ART and recruited between 2018 and 2019 in Franceville, Gabon. VL testing was conducted to assess VL suppression and HIV drug resistance (HIVDR) testing was performed to identify resistance mutations and assess their impact on ongoing and future ART regimens. Results: We recruited 219 participants overall The median time on ART was 27 months and 216/219 participants were on first-Line ART. VL suppression (VL <1000 copies/mL) was 57.1% (95% CI 50.5-63.8) overall; 59.4% (51.4-67.5) and 52.2% (40.3-64.2) for women and men, respectively. The overall prevalence of HIVDR was 21.9% among the study population and 67.2% among those who failed ART. Presence of both NRTI and NNRTI mutations was found in 84.6% of sequences with drug resistance mutations, and full activity of a dolutegra-virbased first-line regimen including tenofovir disoproxil fumarate/lamivudin/dolutegravir was expected only for 5/39 patients with a resistant virus. Conclusions: This study shows a very Low rate of VL suppression in a semi-rural context in Africa. Moreover, the high burden of HIVDR has affected both current and newly recommended ART strategies. Better management of ART in resource-Limited settings is still a challenging ambition.
Plan de classement
Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]
Description Géographique
GABON ; FRANCEVILLE
Localisation
Fonds IRD [F B010082065]
Identifiant IRD
fdi:010082065
Contact